Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BMY with free AI briefings, catalyst countdowns, and dilution alerts.

BMY · BRISTOL MYERS SQUIBB CO

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13B Cash on Hand
CF+ Cash Runway
2.3% Short Interest
$65.25 Analyst Target (24)
Follow BMY by email Get an email when BMY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BMY, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-05-13 Mezigdomide NDA 66%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What BMY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nivolumab
FDA approved Dec 2014 · Opdivo
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction… Phase 2/3 · NCT07221149 Recruiting
Mavacamten
FDA approved Apr 2022 · Camzyos
Non-obstructive Hypertrophic Cardiomyopathy Phase 3 · NCT07940777 Not yet recruiting
Apixaban
FDA approved Dec 2012 · Eliquis
Atrial Fibrillation Phase 3 · NCT05757869 Active not recruiting
Belatacept
FDA approved Jun 2011 · Nulojix
Highly Sensitized Prospective Kidney Transplant Recipients Phase 1/2 · NCT05017545 Active not recruiting
Ipilimumab
FDA approved Mar 2011 · Yervoy
Meningiomas Phase 2 · NCT02648997 Active not recruiting
Fedratinib
FDA approved Aug 2019 · Inrebic
Primary Myelofibrosis Phase 1/2 · NCT04446650 Completed
Luspatercept
FDA approved Nov 2019 · Reblozyl
Myelodysplastic Neoplasms N/A · NCT07752121 Recruiting
Xanomeline Schizophrenia Phase 4 · NCT07221877 Recruiting
FOLFOX Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction… Phase 2/3 · NCT07221149 Recruiting
Izalontamab Brengitecan Non-Small Cell Lung Cancer Phase 3 · NCT07680790 Recruiting
Milvexian Atrial Fibrillation Phase 3 · NCT05757869 Active not recruiting
Nab-paclitaxel Metastatic Non-small Cell Lung Cancer With MTAP Deletion Phase 2/3 · NCT07063745 Recruiting
KarX-EC Schizophrenia Phase 3 · NCT07424404 Recruiting
Osimertinib Non-Small Cell Lung Cancer Phase 3 · NCT07680790 Recruiting
Pumitamig Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction… Phase 2/3 · NCT07221149 Recruiting
Relatlimab Non-small Cell Lung Cancer Phase 3 · NCT06561386 Recruiting

Also used in these trials (approved or third-party drugs, not BMY's own candidates): Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Amivantamab, Atezolizumab, Carboplatin, Bevacizumab, Oxaliplatin, Obinutuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BMY holds $13B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BMY files for a raise →

👥 Who Owns BMY

Insiders 0% Institutions (3354 holders) 84.5% Public and other holders 15.5%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 173,661,963 8.50% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 153,108,018 7.49% 2026-03-31
STATE STREET CORPORATION Institution (13G, 5%+) 102,521,748 5.02% 2026-06-30
Charles Schwab Investment Management, In Institution (13F) 72,453,484 3.54% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 60,215,293 2.95% 2026-09-30
Geode Capital Management, LLC Institution (13F) 50,641,973 2.48% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 47,061,976 2.30% 2026-09-30
Bank of America Corporation Institution (13F) 40,278,707 1.97% 2026-09-30
Morgan Stanley Institution (13F) 28,379,740 1.39% 2026-09-30
David V Elkins
EVP, Chief Financial Officer · +96,067 options
Insider 159,542 0.01% 2026-04-01
Christopher S. Boerner
Chief Executive Officer, Director · +270,924 options
Insider 148,536 0.01% 2026-11-01
Gregory Scott Meyers
EVP, Chief Digital & Tech Off. · +74,881 options
Insider 33,977 0.00% 2026-11-01

Share count 2,044,085,831 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-05
filed 2026-11-06
Haller Julia A
Sale (S) 3,800 $63.31 30,279
2026-11-03
filed 2026-11-04
Lenkowsky Adam
Option exercise (M) 7,522 – 27,228
2026-11-03
filed 2026-11-04
Lenkowsky Adam
Tax withholding (F) 3,848 $61.71 23,380
2026-11-03
filed 2026-11-04
Lenkowsky Adam
Option exercise (M) 7,522 – –
2026-11-01
filed 2026-11-03
BOERNER CHRISTOPHER S.
Option exercise (M) 2,964 – 24,415

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full BMY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.